New pill tested for tough blood cancers after other treatments fail
Disease control
Completed
This early-stage study tested a new oral drug called LP-108, given alone or with another cancer drug (azacitidine), in adults with advanced blood cancers that had returned or did not respond to prior treatments. The main goals were to find a safe dose, see how the body processes …
Phase: PHASE1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC